Abstract: The present invention addresses the problem of providing: a compound exhibiting excellent stability and/or solubility and the like and further improved FLT3 inhibitory activity; and a pharmaceutical composition. The present invention provides a salt or crystal of (S E) N (1 ((5 (2 ((4 cyanophenyl)amino) 4 (propylamino)pyrimidine 5 yl)pent 4 yne 1 yl)amino) 1 oxopropane 2 yl) 4 (dimethylamino) N methylbuto 2 enamide (compound A). This salt or crystal thereof exhibits excellent FLT3 inhibitory activity and excellent properties as a drug such as storage stability solubility or the like; hence said salt or crystal thereof is useful in treating a disease or a condition pertaining to FLT3. The present invention provides a pharmaceutical composition and an FLT3 inhibitor which contain this salt or the crystal thereof.
SOFT COPY ATTACHED IN PDF ONLY
| # | Name | Date |
|---|---|---|
| 1 | Power of Attorney [15-04-2016(online)].pdf | 2016-04-15 |
| 2 | Form 5 [15-04-2016(online)].pdf | 2016-04-15 |
| 3 | Form 3 [15-04-2016(online)].pdf | 2016-04-15 |
| 4 | Form 18 [15-04-2016(online)].pdf | 2016-04-15 |
| 5 | Form 1 [15-04-2016(online)].pdf | 2016-04-15 |
| 6 | Drawing [15-04-2016(online)].pdf | 2016-04-15 |
| 7 | Description(Complete) [15-04-2016(online)].pdf | 2016-04-15 |
| 8 | 201647013238.pdf | 2016-06-08 |
| 9 | 201647013238-OTHERS-260416.pdf | 2016-07-13 |
| 10 | 201647013238-Form 1-260416.pdf | 2016-07-13 |
| 11 | 201647013238-Correspondence-260416.pdf | 2016-07-13 |
| 12 | Form 3 [07-10-2016(online)].pdf | 2016-10-07 |
| 13 | Form 3 [19-01-2017(online)].pdf | 2017-01-19 |
| 14 | 201647013238-FER.pdf | 2018-07-26 |
| 15 | 201647013238-AbandonedLetter.pdf | 2019-01-30 |
| 1 | search_26-07-2018.pdf |